Marc Ladanyi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1943221/publications.pdf

Version: 2024-02-01

253 papers	36,749 citations	4146 87 h-index	3650 180 g-index
259 all docs	259 docs citations	259 times ranked	38309 citing authors

#	Article	IF	Citations
1	Precision medicine in non-small cell lung cancer: Current applications and future directions. Seminars in Cancer Biology, 2022, 84, 184-198.	9.6	106
2	TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas. Endocrine Pathology, 2022, 33, 304-314.	9.0	4
3	Somatic intronic <scp>TP53</scp> c.375+<scp>5G</scp> mutations are a recurrent but underâ€recognized mode of <scp>TP53</scp> inactivation. Journal of Pathology: Clinical Research, 2022, 8, 14-18.	3.0	6
4	Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations. Modern Pathology, 2022, 35, 396-402.	5.5	9
5	TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition. Modern Pathology, 2022, 35, 117-127.	5.5	16
6	Molecular landscape of vulvovaginal squamous cell carcinoma: new insights into molecular mechanisms of HPV-associated and HPV-independent squamous cell carcinoma. Modern Pathology, 2022, 35, 274-282.	5.5	16
7	Molecular Characterization of Peritoneal Mesotheliomas. Journal of Thoracic Oncology, 2022, 17, 455-460.	1.1	24
8	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nature Biotechnology, 2022, 40, 499-506.	17.5	110
9	Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations. JTO Clinical and Research Reports, 2022, 3, 100256.	1.1	4
10	Novel patient-derived models of desmoplastic small round cell tumor confirm a targetable dependency on ERBB signaling. DMM Disease Models and Mechanisms, 2022, 15, .	2.4	11
11	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	2.5	7
12	Functional impact and targetability of PI3KCA, GNAS, and PTEN mutations in a spindle cell rhabdomyosarcoma with MYOD1 L122R mutation. Journal of Physical Education and Sports Management, 2022, 8, a006140.	1.2	6
13	Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer Discovery, 2022, 12, 1233-1247.	9.4	60
14	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	28.9	223
15	The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers. Nature Communications, 2022, 13, 1450.	12.8	47
16	Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data. Journal of Molecular Diagnostics, 2022, 24, 515-528.	2.8	12
17	Salt-Inducible Kinase 1 is a potential therapeutic target in Desmoplastic Small Round Cell Tumor. Oncogenesis, 2022, 11, 18.	4.9	7
18	Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (â‰¥) Tj ETQq0 0 0 rgBT /Overlo	1.6	0

#	Article	IF	Citations
19	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	12.8	63
20	Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 2022, 13, .	12.8	51
21	Clinicopathologic and mutational landscape of BRAF^{V600E}-mutant nonâ€“small cell lung carcinoma.. Journal of Clinical Oncology, 2022, 40, 9084-9084.	1.6	0
22	Comparison of TAS0953/HM06 and selpercatinib in RET fusion-driven preclinical disease models of intracranial metastases.. Journal of Clinical Oncology, 2022, 40, 2024-2024.	1.6	5
23	Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. JCO Precision Oncology, 2022, , .	3.0	3
24	Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma. Modern Pathology, 2021, 34, 490-501.	5.5	18
25	Targeted RNA expression profiling identifies high-grade endometrial stromal sarcoma as a clinically relevant molecular subtype of uterine sarcoma. Modern Pathology, 2021, 34, 1008-1016.	5.5	27
26	Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusionâ€“Positive Lung Cancer by Combining Selpercatinib with Crizotinib. Clinical Cancer Research, 2021, 27, 34-42.	7.0	87
27	Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers. Journal of Thoracic Oncology, 2021, 16, 113-126.	1.1	13
28	Therapeutic Potential of NTRK3 Inhibition in Desmoplastic Small Round Cell Tumor. Clinical Cancer Research, 2021, 27, 1184-1194.	7.0	18
29	A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing. Journal of Molecular Diagnostics, 2021, 23, 253-263.	2.8	20
30	A Performance Comparison of Commonly Used Assays to Detect RET Fusions. Clinical Cancer Research, 2021, 27, 1316-1328.	7.0	39
31	The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response. Human Mutation, 2021, 42, 150-163.	2.5	0
32	Malignant transformation of a polymorphous low grade neuroepithelial tumor of the young (PLNTY). Acta Neuropathologica, 2021, 141, 123-125.	7.7	26
33	RET inhibition in novel patient-derived models of RET fusion- positive lung adenocarcinoma reveals a role for MYC upregulation. DMM Disease Models and Mechanisms, 2021, 14, .	2.4	9
34	Nextâ€generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline. Histopathology, 2021, 78, 498-507.	2.9	7
35	The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics, 2021, 53, 11-15.	21.4	139
36	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 729.	12.8	212

#	Article	IF	Citations
37	Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12Câ€“Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 2209-2215.	7.0	65
38	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	13.2	74
39	Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas. Clinical Cancer Research, 2021, 27, 2613-2623.	7.0	49
40	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. Molecular Cancer Research, 2021, 19, 1146-1155.	3.4	14
41	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clinical Cancer Research, 2021, 27, 2920-2927.	7.0	42
42	Structureâ€“function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targeting. Nature Communications, 2021, 12, 1382.	12.8	34
43	Rapid EGFR Mutation Detection Using the Idylla Platform. Journal of Molecular Diagnostics, 2021, 23, 310-322.	2.8	19
44	The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. Clinical Cancer Research, 2021, 27, 3154-3166.	7.0	26
45	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	8.2	26
46	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. Clinical Cancer Research, 2021, 27, 4066-4076.	7.0	45
47	Extracellular signal-regulated kinase mediates chromatin rewiring and lineage transformation in lung cancer. ELife, 2021, 10, .	6.0	16
48	Clinical Experience of Cerebrospinal Fluidâ€“Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling. Journal of Molecular Diagnostics, 2021, 23, 742-752.	2.8	17
49	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	12.8	68
50	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. Modern Pathology, 2021, 34, 2122-2129.	5.5	17
51	Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers. Journal of Thoracic Oncology, 2021, 16, 1149-1165.	1.1	18
52	Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling. Journal of Thoracic Oncology, 2021, 16, 1188-1199.	1.1	23
53	Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas. Sarcoma, 2021, 2021, 1-7.	1.3	1
54	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , .	6.3	6

#	Article	IF	Citations
55	Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer. Nature Communications, 2021, 12, 4789.	12.8	21
56	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	1.6	83
57	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. Bladder Cancer, 2021, 7, 1-6.	0.4	2
58	Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy. Gynecologic Oncology Reports, 2021, 37, 100852.	0.6	12
59	The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. The Lancet Digital Health, 2021, 3, e565-e576.	12.3	23
60	ROS1 at the Crossroads of Clinical Oncology, Molecular Diagnostics, and Drug Development. JCO Oncology Practice, 2021, 17, 15-16.	2.9	1
61	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237
62	Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. European Urology Oncology, 2021, 4, 993-1000.	5.4	16
63	Clonal hematopoiesis is associated with risk of severe Covid-19. Nature Communications, 2021, 12, 5975.	12.8	81
64	Pan-Cancer Biomarkers: Changing the Landscape of Molecular Testing. Archives of Pathology and Laboratory Medicine, 2021, 145, 692-698.	2.5	10
65	The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585.	21.4	44
66	Immuno-transcriptomic profiling of extracranial pediatric solid malignancies. Cell Reports, 2021, 37, 110047.	6.4	26
67	V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. Modern Pathology, 2020, 33, 303-311.	5.5	65
68	Genomic Profiling Identifies Association of IDH1/IDH2 Mutation with Longer Relapse-Free and Metastasis-Free Survival in High-Grade Chondrosarcoma. Clinical Cancer Research, 2020, 26, 419-427.	7.0	60
69	NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Modern Pathology, 2020, 33, 38-46.	5.5	373
70	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology, 2020, 6, 84.	7.1	66
71	Reliable Clinical MLH1 Promoter Hypermethylation Assessment Using a High-Throughput Genome-Wide Methylation Array Platform. Journal of Molecular Diagnostics, 2020, 22, 368-375.	2.8	25
72	Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. Journal of Thoracic Oncology, 2020, 15, 655-660.	1.1	25

#	Article	IF	Citations
73	Retained mismatch repair protein expression occurs in approximately 6% of microsatellite instability-high cancers and is associated with missense mutations in mismatch repair genes. Modern Pathology, 2020, 33, 871-879.	5.5	58
74	SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. Journal of Thoracic Oncology, 2020, 15, 231-247.	1.1	172
75	The epigenomics of sarcoma. Nature Reviews Cancer, 2020, 20, 608-623.	28.4	121
76	The Genomic Landscape of SMARCA4 Alterations and Associations with Outcomes in Patients with Lung Cancer. Clinical Cancer Research, 2020, 26, 5701-5708.	7.0	133
77	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. Urology, 2020, 144, 111-116.	1.0	5
78	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	21.4	367
79	CNS Metastases in Patients With MET Exon 14â€“Altered Lung Cancers and Outcomes With Crizotinib. JCO Precision Oncology, 2020, 4, 871-876.	3.0	14
80	NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors. Communications Biology, 2020, 3, 776.	4.4	34
81	Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precision Oncology, 2020, 4, 1350-1360.	3.0	18
82	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. JCO Precision Oncology, 2020, 4, 1280-1284.	3.0	1
83	Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions. Acta Neuropathologica Communications, 2020, 8, 186.	5.2	26
84	Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers. JAMA Oncology, 2020, 6, 1048.	7.1	96
85	BCOR Expression in Mullerian Adenosarcoma. American Journal of Surgical Pathology, 2020, 44, 765-770.	3.7	21
86	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. Clinical Cancer Research, 2020, 26, 2932-2945.	7.0	35
87	Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma. Modern Pathology, 2020, 33, 2244-2255.	5.5	23
88	Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 507-516.	3.9	10
89	Development, Validation, and Regulatory Considerations for a Liquid Biopsy Test. Clinical Chemistry, 2020, 66, 408-414.	3.2	8
90	Infarction with associated pseudosarcomatous changes mimics anaplasia in otherwise grade I meningiomas. Modern Pathology, 2020, 33, 1298-1306.	5.5	2

#	Article	IF	Citations
91	Uterine Cervical Sarcoma With a Novel RET-SPECC1L Fusion in an Adult. American Journal of Surgical Pathology, 2020, 44, 567-570.	3.7	18
92	Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer. Clinical Cancer Research, 2020, 26, 2654-2663.	7.0	230
93	Ultrarapid EGFR Mutation Screening Followed by Comprehensive Next-Generation Sequencing: AÂFeasible, Informative Approach for Lung Carcinoma Cytology Specimens With a High Success Rate. JTO Clinical and Research Reports, 2020, 1, 100077.	1.1	18
94	Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clinical Cancer Research, 2019, 25, 1063-1069.	7.0	257
95	Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine, 2019, 25, 1422-1427.	30.7	144
96	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 6160-6169.	7.0	73
97	Concurrent RB1 and TP53 Alterations Define aÂSubset of EGFR-Mutant Lung Cancers at risk forÂHistologic Transformation and Inferior Clinical Outcomes. Journal of Thoracic Oncology, 2019, 14, 1784-1793.	1.1	232
98	Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. Acta OncolÃ³gica, 2019, 58, 1634-1639.	1.8	10
99	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	27.8	295
100	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	7.0	107
101	RUNX2 (6p21.1) amplification in osteosarcoma. Human Pathology, 2019, 94, 23-28.	2.0	13
102	Histone H3K36I mutation in a metastatic histiocytic tumor of the skull and response to sarcoma chemotherapy. Journal of Physical Education and Sports Management, 2019, 5, a004606.	1.2	8
103	Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. Journal of Thoracic Oncology, 2019, 14, 1989-1994.	1.1	10
104	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach. Clinical Cancer Research, 2019, 25, 7113-7125.	7.0	69
105	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 7475-7484.	7.0	30
106	Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements. Journal of Thoracic Oncology, 2019, 14, 825-834.	1.1	62
107	Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations. Clinical Cancer Research, 2019, 25, 6346-6356.	7.0	75
108	DNA methylation-based classification of sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 1447-1459.	5.5	82

#	Article	IF	Citations
109	Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. Journal of Thoracic Oncology, 2019, 14, 802-815.	1.1	71
110	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. Modern Pathology, 2019, 32, 1344-1358.	5.5	49
111	High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clinical Cancer Research, 2019, 25, 4712-4722.	7.0	292
112	Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors. American Journal of Surgical Pathology, 2019, 43, 382-388.	3.7	53
113	Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices. Modern Pathology, 2019, 32, 1106-1122.	5.5	58
114	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusionâ€“Driven Cancer. Cancer Discovery, 2019, 9, 605-616.	9.4	11
115	Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma. Genome Medicine, 2019, 11, 18.	8.2	36
116	Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. Journal of Physical Education and Sports Management, 2019, 5, a003665.	1.2	23
117	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	1.6	397
118	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	30.7	122
119	Undifferentiated Uterine Sarcomas Represent Under-Recognized High-grade Endometrial Stromal Sarcomas. American Journal of Surgical Pathology, 2019, 43, 662-669.	3.7	61
120	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	30.7	485
121	JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy. Human Pathology, 2019, 88, 87-91.	2.0	20
122	MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. Modern Pathology, 2019, 32, 27-36.	5.5	126
123	Next-Generation Sequencingâ€“Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer. Journal of Molecular Diagnostics, 2019, 21, 307-317.	2.8	19
124	Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Modern Pathology, 2019, 32, 609-620.	5.5	112
125	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	21.4	2,702
126	Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. Cancer Research, 2019, 79, 1047-1053.	0.9	112

#	Article	IF	Citations
127	Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14â€“mutant Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 1248-1260.	7.0	92
128	A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers. Journal of the National Cancer Institute, 2019, 111, 575-583.	6.3	96
129	Association of BAP1 alterations with malignant pleural mesothelioma treated with trimodality therapy.. Journal of Clinical Oncology, 2019, 37, 8552-8552.	1.6	1
130	MET inhibitor resistance in patients with MET exon 14-altered lung cancers.. Journal of Clinical Oncology, 2019, 37, 9006-9006.	1.6	24
131	Molecular correlates of PD-L1 expression in patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 9018-9018.	1.6	5
132	Tissue-based molecular and histological landscape of acquired resistance to osimertinib given initially or at relapse in patients with EGFR-mutant lung cancers.. Journal of Clinical Oncology, 2019, 37, 9028-9028.	1.6	22
133	Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer.. Journal of Clinical Oncology, 2019, 37, 3585-3585.	1.6	1
134	Tumor volumetric correlation with plasma cell free DNA (cfDNA) mutation detection in metastatic lung cancers.. Journal of Clinical Oncology, 2019, 37, e14610-e14610.	1.6	1
135	Clinicopathologic characteristics of NRG1 fusion-positive cancers: A single-institution study.. Journal of Clinical Oncology, 2019, 37, 3129-3129.	1.6	0
136	Efficacy of Larotrectinib inTRKFusionâ€“Positive Cancers in Adults and Children. New England Journal of Medicine, 2018, 378, 731-739.	27.0	2,036
137	The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. Cancer Cell, 2018, 33, 527-541.e8.	16.8	99
138	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	6.4	801
139	The molecular pathology of cancer: from panâ€genomics to postâ€genomics. Journal of Pathology, 2018, 244, 509-511.	4.5	50
140	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	9.4	275
141	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	16.8	589
142	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.	6.2	284
143	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical Cancer Research, 2018, 24, 3108-3118.	7.0	200
144	Effects of Co-occurring Genomic Alterations on Outcomes in Patients withKRAS-Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 334-340.	7.0	323

#	Article	IF	Citations
145	Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. Modern Pathology, 2018, 31, 111-121.	5.5	50
146	ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity. Modern Pathology, 2018, 31, 674-684.	5.5	130
147	Therapeutic Potential of Afatinib for Cancers with ERBB2 (HER2) Transmembrane Domain Mutations G660D and V659E. Oncologist, 2018, 23, 150-154.	3.7	25
148	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	9.4	275
149	RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Nonâ€“Small Cell Lung Carcinomas Sensitive to MEK Inhibition. Clinical Cancer Research, 2018, 24, 1436-1447.	7.0	56
150	Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery, 2018, 8, 1548-1565.	9.4	422
151	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	16.8	633
152	Fusion oncogenesâ€”genetic musical chairs. Science, 2018, 361, 848-849.	12.6	4
153	Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma. Clinical Cancer Research, 2018, 24, 6471-6482.	7.0	42
154	Bronchiolar Adenoma. American Journal of Surgical Pathology, 2018, 42, 1010-1026.	3.7	91
155	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. JAMA Oncology, 2018, 4, 1228.	7.1	132
156	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	7.0	100
157	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2027-2033.	1.5	19
158	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncology, 2018, 4, 1589.	7.1	139
159	YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6030-E6038.	7.1	44
160	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. Blood, 2018, 132, 49-49.	1.4	10
161	PPP2R1A regulated by PAX3/FOXO1 fusion contributes to the acquisition of aggressive behavior in PAX3/FOXO1-positive alveolar rhabdomyosarcoma. Oncotarget, 2018, 9, 25206-25215.	1.8	7
162	MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation. Nature Communications, 2017, 8, 14674.	12.8	53

#	Article	IF	Citations
163	Generation of conditional oncogenic chromosomal translocations using <scp>CRISPR</scp>â€“Cas9 genomic editing and homologyâ€directed repair. Journal of Pathology, 2017, 242, 102-112.	4.5	23
164	Chromosome 20q Amplification Defines a Subtype of Microsatellite Stable, Left-Sided Colon Cancers with Wild-type RAS/RAF and Better Overall Survival. Molecular Cancer Research, 2017, 15, 708-713.	3.4	24
165	Identification of NTRK3 Fusions in Childhood Melanocytic Neoplasms. Journal of Molecular Diagnostics, 2017, 19, 387-396.	2.8	36
166	Universal screening for microsatellite instability in colorectal cancer in the clinical genomics era: new recommendations, methods, and considerations. Familial Cancer, 2017, 16, 525-529.	1.9	18
167	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer. Cancer Research, 2017, 77, 2990-3000.	0.9	106
168	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
169	BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology. Modern Pathology, 2017, 30, 1251-1261.	5.5	112
170	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	9.4	490
171	Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations. Clinical Cancer Research, 2017, 23, 2981-2990.	7.0	61
172	Next-Generation Assessment of Human Epidermal Growth Factor Receptor 2 (ERBB2) Amplification Status. Journal of Molecular Diagnostics, 2017, 19, 244-254.	2.8	96
173	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	7.4	366
174	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	11.1	578
175	Comprehensive detection of germline variants by MSK-IMPACT, a clinical diagnostic platform for solid tumor molecular oncology and concurrent cancer predisposition testing. BMC Medical Genomics, 2017, 10, 33.	1.5	111
176	Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathologica, 2017, 133, 417-429.	7.7	172
177	Identification and Functional Characterization of EGFR V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. JCO Precision Oncology, 2017, 1, 1-10.	3.0	9
178	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	286
179	DNA Methylationâ€“Based Classifier for Accurate Molecular Diagnosis of Bone Sarcomas. JCO Precision Oncology, 2017, 2017, 1-11.	3.0	37
180	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	3.0	1,266

#	Article	IF	Citations
181	Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas. JCO Precision Oncology, 2017, 2017, 1-11.	3.0	36
182	Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma. Oncotarget, 2016, 7, 50875-50882.	1.8	26
183	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 2016, 7, 8613-8624.	1.8	55
184	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <scp>TERT</scp> promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	4.5	102
185	Genomic aberrations frequently alter chromatin regulatory genes in chordoma. Genes Chromosomes and Cancer, 2016, 55, 591-600.	2.8	58
186	Current state of pediatric sarcoma biology and opportunities for future discovery: A report from the sarcoma translational research workshop. Cancer Genetics, 2016, 209, 182-194.	0.4	38
187	Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma. Cancer Research, 2016, 76, 6095-6106.	0.9	30
188	Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples. Journal of Molecular Diagnostics, 2016, 18, 903-911.	2.8	20
189	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Science Signaling, 2016, 9, ra33.	3.6	54
190	Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial. Lancet Oncology, The, 2016, 17, 1653-1660.	10.7	365
191	Expression of F-actin-capping protein subunit beta, CAPZB, is associated with cell growth and motility in epithelioid sarcoma. BMC Cancer, 2016, 16, 206.	2.6	10
192	Proteasome Addiction Defined in Ewing Sarcoma Is Effectively Targeted by a Novel Class of 19S Proteasome Inhibitors. Cancer Research, 2016, 76, 4525-4534.	0.9	33
193	Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric Blood and Cancer, 2016, 63, 1368-1374.	1.5	49
194	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104.	7.1	270
195	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinomaâ€“like and Nonâ€“Small Cell Carcinomaâ€“like Subsets. Clinical Cancer Research, 2016, 22, 3618-3629.	7.0	342
196	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research, 2016, 14, 296-301.	3.4	46
197	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer. Clinical Cancer Research, 2016, 22, 2351-2358.	7.0	141
198	Cancer Genomics: Large-Scale Projects Translate into Therapeutic Advances. PLoS Medicine, 2016, 13, e1002209.	8.4	1

#	Article	IF	Citations
199	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer, 2015, 121, 3212-3220.	4.1	160
200	Consistent copy number changes and recurrent <scp>PRKAR1A</scp> mutations distinguish <scp>M</scp>elanotic <scp>S</scp>chwannomas from <scp>M</scp>elanomas: <scp>SNP</scp>â€array and next generation sequencing analysis. Genes Chromosomes and Cancer, 2015, 54, 463-471.	2.8	44
201	GENO-35NGS-BASED MSK-IMPACT ANALYSIS REVEALS SPECIFIC GENETIC ALTERATIONS IN RECURRENT GLIOBLASTOMA. Neuro-Oncology, 2015, 17, v99.4-v99.	1.2	0
202	Synovial Sarcoma: Recent Discoveries as a Roadmap to New Avenues for Therapy. Cancer Discovery, 2015, 5, 124-134.	9.4	135
203	Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping. Cancer Discovery, 2015, 5, 842-849.	9.4	514
204	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases. Cancer Discovery, 2015, 5, 610-621.	9.4	129
205	MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clinical Cancer Research, 2015, 21, 1935-1943.	7.0	124
206	AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants. Molecular Cancer Research, 2015, 13, 1003-1008.	3.4	20
207	Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). Journal of Molecular Diagnostics, 2015, 17, 251-264.	2.8	1,566
208	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature, 2015, 526, 453-457.	27.8	191
209	Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor. JAMA Oncology, 2015, 1, 982.	7.1	214
210	EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer Discovery, 2015, 5, 1155-1163.	9.4	94
211	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today, 2015, 20, 1422-1428.	6.4	136
212	Optimizing the Sequence of Anti-EGFRâ€“Targeted Therapy in EGFR-Mutant Lung Cancer. Molecular Cancer Therapeutics, 2015, 14, 542-552.	4.1	28
213	BAP1 Missense Mutation c.2054 A>T (p.E685V) Completely Disrupts Normal Splicing through Creation of a Novel 5â€™ Splice Site in a Human Mesothelioma Cell Line. PLoS ONE, 2015, 10, e0119224.	2.5	9
214	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics, 2014, 46, 595-600.	21.4	152
215	Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage. Modern Pathology, 2014, 27, 875-886.	5.5	136
216	EWSâ€“WT1 Oncoprotein Activates Neuronal Reprogramming Factor ASCL1 and Promotes Neural Differentiation. Cancer Research, 2014, 74, 4526-4535.	0.9	30

#	Article	IF	Citations
217	Merlin/NF2 Loss-Driven Tumorigenesis Linked to CRL4DCAF1-Mediated Inhibition of the Hippo Pathway Kinases Lats1 and 2 in the Nucleus. Cancer Cell, 2014, 26, 48-60.	16.8	198
218	Rationale for co-targeting IGF-1R and ALK in ALK fusionâ€“positive lung cancer. Nature Medicine, 2014, 20, 1027-1034.	30.7	243
219	Combining integrated genomics and functional genomics to dissect the biology of a cancerâ€associated, aberrant transcription factor, the <scp>ASPSCR1â€“TFE3</scp> fusion oncoprotein. Journal of Pathology, 2013, 229, 743-754.	4.5	58
220	New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment. Clinical Cancer Research, 2012, 18, 4485-4490.	7.0	77
221	Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions. Clinical Cancer Research, 2012, 18, 6599-6608.	7.0	169
222	PDGF Receptor Alpha Is an Alternative Mediator of Rapamycin-Induced Akt Activation: Implications for Combination Targeted Therapy of Synovial Sarcoma. Cancer Research, 2012, 72, 4515-4525.	0.9	68
223	Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways. Clinical Cancer Research, 2012, 18, 748-757.	7.0	203
224	Optimization of Dosing for EGFR-Mutant Nonâ€“Small Cell Lung Cancer with Evolutionary Cancer Modeling. Science Translational Medicine, 2011, 3, 90ra59.	12.4	457
225	Cancer biology and genomics: translating discoveries, transforming pathology. Journal of Pathology, 2011, 223, 99-101.	4.5	6
226	CRKL as a Lung Cancer Oncogene and Mediator of Acquired Resistance to EGFR Inhibitors: Is It All That It Is Cracked Up to Be?. Cancer Discovery, 2011, 1, 560-561.	9.4	5
227	The 2010 Fred W. Stewart Award Recipient. American Journal of Surgical Pathology, 2011, 35, 455-456.	3.7	0
228	Targeted therapy of cancer: new roles for pathologists. Modern Pathology, 2008, 21, S1-S1.	5.5	13
229	Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Modern Pathology, 2008, 21, S16-S22.	5.5	313
230	TFE3 Fusions Activate MET Signaling by Transcriptional Up-regulation, Defining Another Class of Tumors as Candidates for Therapeutic MET Inhibition. Cancer Research, 2007, 67, 919-929.	0.9	275
231	Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer, 2005, 49, S95-S98.	2.0	69
232	The Precrystalline Cytoplasmic Granules of Alveolar Soft Part Sarcoma Contain Monocarboxylate Transporter 1 and CD147. American Journal of Pathology, 2002, 160, 1215-1221.	3.8	109
233	Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Research, 2002, 62, 135-40.	0.9	390
234	EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights. Cancer Biology and Therapy, 2002, 1, 330-6.	3.4	19

#	Article	IF	Citations
235	Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen ny-eso-1 but not mage-a1 or ct7. International Journal of Cancer, 2001, 94, 252-256.	5.1	182
236	Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nature Medicine, 2001, 7, 673-679.	30.7	2,352
237	The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene, 2001, 20, 48-57.	5.9	562
238	Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene, 2001, 20, 5755-5762.	5.9	204
239	Prognostic impact of P53 status in Ewing sarcoma. Cancer, 2000, 89, 783-792.	4.1	138
240	Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer, 2000, 89, 793-799.	4.1	98
241	CDK4 gene amplification in osteosarcoma: Reciprocal relationship withINK4A gene alterations and mapping of 12q13 amplicons. , 1999, 80, 199-204.		111
242	Synovial sarcoma mimicking desmoplastic small round-cell tumor: Critical role for molecular diagnosis. , 1999, 32, 97-101.		21
243	Skeletal and extraskeletal myxoid chondrosarcoma. Cancer, 1998, 83, 1504-1521.	4.1	194
244	The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nature Genetics, 1997, 17, 309-313.	21.4	166
245	p53 and MDM2 alterations in osteosarcomas. , 1997, 79, 1541-1547.		125
246	p53 and MDM2 alterations in osteosarcomas. Cancer, 1997, 79, 1541-1547.	4.1	4
247	LETTER TO THE EDITOR. SPECIFICITY OF THE EWS/WT1 GENE FUSION FOR DESMOPLASTIC SMALL ROUND CELL TUMOUR. , 1996, 180, 462-462.		18
248	MDM2 andCDK4 gene amplification in Ewing's sarcoma. Journal of Pathology, 1995, 175, 211-217.	4.5	95
249	Structural Alterations in the 5â€² Region of the BCL2 Gene in Follicular Lymphomas WithBCL2-MBR orBCL2-MCR Rearrangements. Genes Chromosomes and Cancer, 1991, 3, 117-121.	2.8	22
250	Clonal cytogenetic abnormalities in Hodgkin's disease. Genes Chromosomes and Cancer, 1991, 3, 294-299.	2.8	36
251	Immunohistochemical, molecular, and cytogenetic analysis of a consecutive series of 20 peripheral t-cell lymphomas and lymphomas of uncertain lineage, including 12 Ki-1 positive lymphomas. Genes Chromosomes and Cancer, 1990, 2, 27-35.	2.8	50
252	Leukemic differentiation of a mediastinal germ cell tumor. Genes Chromosomes and Cancer, 1989, 1, 83-87.	2.8	109

#	Article	IF	Citations
253	Benign metastasizing giant cell tumors of bone. A DNA flow cytometric study. Cancer, 1989, 64, 1521-1526.	4.1	68